Cargando…

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia

Mutations involving epigenetic regulators (TET2~60% and ASXL1~40%) and splicing components (SRSF2~50%) are frequent in chronic myelomonocytic leukemia (CMML). On a 27-gene targeted capture panel performed on 175 CMML patients (66% males, median age 70 years), common mutations included: TET2 46%, ASX...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patnaik, M M, Lasho, T L, Vijayvargiya, P, Finke, C M, Hanson, C A, Ketterling, R P, Gangat, N, Tefferi, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742630/ https://www.ncbi.nlm.nih.gov/pubmed/26771811 http://dx.doi.org/10.1038/bcj.2015.113

Ejemplares similares

EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimental
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance
por: Patnaik, M M, et al.
Publicado: (2016)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia
por: Lasho, T L, et al.
Publicado: (2015)

ASXL1 mutated chronic myelomonocytic leukemia in a patient with familial thrombocytopenia secondary to germline mutation in ANKRD26
por: Perez Botero, J, et al.
Publicado: (2015)

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
por: Patnaik, M M, et al.
Publicado: (2015)

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis
por: Patnaik, M M, et al.
Publicado: (2017)

P709: H2AK119UB IN THE TRANSCRIPTIONAL REGULATION OF PATIENTS WITH ASXL1-MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Binder, Moritz, et al.
Publicado: (2023)

Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia
por: Binder, Moritz, et al.
Publicado: (2022)

Blast Phase Chronic Myelomonocytic Leukemia: Mayo-MDACC Collaborative study of 171 cases
por: Patnaik, Mrinal M., et al.
Publicado: (2018)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
por: Kim, Hyun-Young, et al.
Publicado: (2018)

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
por: Cerquozzi, S., et al.
Publicado: (2017)

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
por: Barraco, D, et al.
Publicado: (2016)

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations
por: Barraco, D, et al.
Publicado: (2016)

P726: TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA
por: Wang, Yu-Hung, et al.
Publicado: (2023)

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
por: Gangat, Naseema, et al.
Publicado: (2019)

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
por: Patnaik, M M, et al.
Publicado: (2010)

Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q)
por: Tefferi, Ayalew, et al.
Publicado: (2017)

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
por: Nicolosi, Maura, et al.
Publicado: (2018)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
por: Szuber, Natasha, et al.
Publicado: (2018)

Leukocytosis and presence of CALR mutation is associated with non-hepatosplenic extramedullary hematopoiesis in primary myelofibrosis
por: Barraco, D, et al.
Publicado: (2016)

Genetic predictors of response to specific drugs in primary myelofibrosis
por: Penna, Domenico, et al.
Publicado: (2018)

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin
por: Batta, Kiran, et al.
Publicado: (2021)

Acute Myeloid Leukemia with Co-mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia
por: Johnson, Steven M., et al.
Publicado: (2019)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

TET2 mutational status affects myelodysplastic syndrome evolution to chronic myelomonocytic leukemia
por: Quang, Violaine Tran, et al.
Publicado: (2023)

Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations
por: Barraco, D, et al.
Publicado: (2017)

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
por: Vallapureddy, Rangit R., et al.
Publicado: (2019)

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival
por: Szuber, Natasha, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tatdhavqd3pnm00hfni04vv7ai